Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial

Prespecified interim analysis (n=40,382;United Arab Emirates, Bahrain) found two inactivated SARS-CoV-2 vaccines developed from SARS-CoV-2 WIV04 (5 µg/dose) or HB02 (4 µg/dose) strains showed efficacy against symptomatic COVID-19 (72.8% & 78.1%) vs. aluminum hydroxide-control.

Journal of the American Medical Association